This inventor holds 20 USPTO granted patents and 5 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Vaccine Development. Top assignees: Transgene S.a., Transgene, Other. Active years: 1998-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Strasbourg, FR (1998 - 2002)
- Ergersheim, FR (2012 - 2024)
Company Filing History:
Years Active: 1998-2024
Areas of Expertise:
Title: **Nathalie Silvestre: Pioneering Personalized Immunotherapy**
Introduction
Nathalie Silvestre, based in Ergersheim, France, is a prominent innovator in the field of biotechnology. With an impressive portfolio of 20 patents, she has made significant contributions towards advancing personalized immunotherapy, particularly in cancer treatment. Her work continues to impact the medical community and offers hope to many suffering from cancer.
Latest Patents
Nathalie Silvestre's latest patents include groundbreaking inventions that focus on personalized vaccines and oncolytic viruses. One notable patent describes a personalized cancer vaccine that utilizes a recombinant poxvirus encoding one or more neopeptides. This innovative approach involves sequencing DNA from both tumor and non-tumor samples to identify specific tumor mutations, paving the way for tailored treatment methods. The second patent involves an oncolytic virus engineered to express immune checkpoint modulators, providing therapeutic options for treating proliferative diseases, including various forms of cancer. Both patents highlight her commitment to developing targeted therapies that cater to individual patient needs.
Career Highlights
Silvestre has worked with organizations such as Transgene S.A., where she honed her expertise in cancer therapeutics. Throughout her career, her efforts have focused on harnessing the power of personalized medicine to improve patient outcomes in oncology.
Collaborations
In her journey, Nathalie has collaborated with noteworthy individuals in the field, including Jean-Baptiste Marchand and Perrine Martin. These partnerships have fostered innovative research and development, further advancing the impact of her work in cancer immunotherapy.
Conclusion
Nathalie Silvestre stands out as a leading inventor in the realm of personalized cancer treatment. Her innovative patents, commitment to research, and collaborative spirit continue to drive advancements in immunotherapy. As she forges ahead, her contributions herald a new era in cancer treatment, emphasizing the importance of personalized medicine in improving patient care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile